References

  1. Kutikov A, Crispen PL, Uzzo RG. Pathophysiology, Evaluation, and Medical Management of Adrenal Disorders. In: Wein AJ, Kavoussi LR, Partin AW, et al, ed; Campbell-Walsh Urology, 10th ed. Philadelphia: Elsevier; 2011:1685-1736.

  2. Mitty HA. Embryology, anatomy, and anomalies of the adrenal gland. Semin Roentgenol 1988;23:271-279.

  3. Avisse C, Marcus C, Patey M, et al. Surgical anatomy and embryology of the adrenal glands. Surg Clin North Am 2000;80: 403-415.

  4. Silverman ML, Lee AK. Anatomy and pathology of the adrenal glands. Urol Clin North Am 1989;16:417-432.

  5. 5. Barwick TD, Malhotra A, Webb JA, et al. Embryology of the adrenal glands and its relevance to diagnostic imaging. Clin Radiol 2005;60:953-959.

  6. Kempná P, Flück CE. Adrenal gland development and defects. Best Pract Res Clin Endocrinol Metab 2008;22:77-93.

  7. Arlt W, Stewart PM. Adrenal corticosteroid 
biosynthesis, metabolism, and action. Endocrinol Metab Clin North Am 2005;34:293-313.

  8. Rainey WE. Adrenal zonation: clues from 
11beta-hydroxylase and aldosterone synthase. 
Mol Cell Endocrinol 1999;151:151-160.

  9. Jacobson L. Hypothalamic-pituitary-adrenocortical axis regulation. Endocrinol Metab Clin North Am 2005;34:271-292. 

  10. Gibbons GH, Dzau VJ, Farhi ER, Barger AC. 
Interaction of signals influencing renin release. 
Annu Rev Physiol 1984;46:291-308.

  11. de Diego AM, Gandia L, Garcia AG. A physiological view of the central and peripheral mechanisms that regulate the release of catecholamines at the adrenal medulla. Acta Physiol (Oxf) 2008;192:287-301. 

  12. Robertson D. The Adrenal Medulla and Adrenomedullary Hormones. In: Scott WH, ed; Surgery of the adrenal glands. Philadelphia: JB Lippincott;1990:55-68.

  13. Pivonello R, De Martino MC, De Leo M, et al. 
Cushing’s Syndrome. Endocrinol Metab Clin North Am 2008;37:135-149. 

  14. Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing’s syndrome. N Engl J Med 1971;285:243-247. 

  15. Lindholm J, Juul S, Jorgensen JO, et al. Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 2001;86:117-123. 

  16. Findling JW, Raff H. Screening and diagnosis of ­Cushing’s syndrome. Endocrinol Metab Clin North Am 2005;34:385-402.

  17. Porterfield JR, Thompson GB, Young WF Jr, et al. Surgery for Cushing’s syndrome: an historical review and recent ten-year experience. World J Surg 2008;32:659-677.

  18. Orth DN. Cushing’s Syndrome. N Engl J Med 1995;332:791-803.

  19. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing’s syndrome. Lancet 2006;367:1605-1617.

  20. Scott WH, Orth DN. Hypercortisolism (Cushing’s Syndrome). In: Scott WH, ed; Surgery of the Adrenal Glands. Philadelphia: JB Lippincott;1990;115-151.

  21. Young WF Jr, du Plessis H, Thompson GB, et al. The clinical conundrum of corticotropin-independent autonomous cortisol secretion in patients with bilateral adrenal masses. World J Surg 2008;32:856-862.

  22. Lacroix A, Bourdeau I. Bilateral adrenal Cushing’s syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease. Endocrinol Metab Clin North Am 2005;34:441-458.

  23. Pivonello R, Faggiano A, Lombardi G, Colao A. The metabolic syndrome and cardiovascular risk 
in ­Cushing’s syndrome. Endocrinol Metab Clin 
North Am 2005;34:327-339.

  24. Faggiano A, Pivonello R, Melis D, et al. Nephro­lithiasis in Cushing’s disease: prevalence, etiopatho­genesis, and modification after disease cure. 
J Clin Endocrinol Metab 2003;88:2076-2080.

  25. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93:1526-1540.

  26. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med 2003;138:980-991.

  27. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003;88:5593-5602.

  28. Findling JW, Raff H. Cushing’s syndrome: 
important issues in diagnosis and management. 
J Clin Endocrinol Metab 2006;91:3746-3753.

  29. Utz AL, Swearingen B, Biller BM. Pituitary surgery and postoperative management in Cushing’s disease. Endocrinol Metab Clin North Am 2005;34:459-478.

  30. Chow JT, Thompson GB, Grant CS, et al. Bilateral laparoscopic adrenalectomy for corticotrophin-dependent Cushing’s syndrome: a review of the Mayo Clinic experience. Clin Endocrinol (Oxf) 2008;68:513-519.

  31. Vella A, Thompson GB, Grant CS, et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab, 2001;86:1596-1599.

  32. Lacroix A. Evaluation of bilateral laparoscopic adrenalectomy in adrenocorticotropic hormone-dependent Cushing’s syndrome. Nat Clin Pract Endocrinol Metab 2008;4:310-311.

  33. Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome. 
J Clin Endocrinol Metab 2007;92:172-179.

  34. Aniszewski JP, Young WF Jr, Thompson GB, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg 2001;25:934-940.

  35. Walz MK. Extent of adrenalectomy for adrenal neoplasm: cortical sparing (subtotal) versus total adrenalectomy. Surg Clin North Am 2004;84:743-753.

  36. Mulatero P, Stowasser M, Loh KC, et al. Increased 
diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. 
J Clin Endocrinol Metab 2004;89:1045-1050.

  37. Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300.

  38. Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 2007;66:607-618.

  39. Mulatero P, Stowasser M, Loh KC, et al. Increased 
diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. 
J Clin Endocrinol Metab 2004;89:1045-1050.

  40. Young WF Jr. The incidentally discovered adrenal mass. N Engl J Med 2007;356: 601-610.

  41. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003;138:424-429.

  42. Vierhapper H. Determination of the aldosterone/renin ratio in 269 patients with adrenal incidentaloma. 
Exp Clin Endocrinol Diabetes 2007;115:518-521.

  43. Adler JT, Mack E, Chen H. Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol 2007;14:2358-2362,

  44. Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000;29:159-185.

  45. Young WF, Stanson AW, Thompson GB, et al. 
Role for adrenal venous sampling in primary 
aldosteronism. Surgery 2004;136:1227-1235.

  46. Young WF, Stanson AW. What are the keys to ­successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 2009;70:14-17.

  47. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 
11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992;355:262-265.

  48. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003;24:539-553.

  49. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005;366:665-675.

  50. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. New Engl J Med 2002;346:1459-1466.

  51. Boland GW. Adrenal imaging: why, when, what, and how? Part 1. Why and when to image? AJR Am J Roentgenol 2010;195:W377-W381.

  52. Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology 2008;249:756-775.

  53. Adler JT, Meyer-Rochow GY, Chen H, et al. 
Pheochromocytoma: current approaches and future directions. Oncologist 2008;13:779-793.

  54. Benn DE, Robinson BG. Genetic basis of 
phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab 2006;20:435-450.

  55. Ilias I, Pacak K. Current approaches and 
recommended algorithm for the diagnostic 
localization of pheochromocytoma. J Clin 
Endocrinol Metab 2004;89:479-491.

  56. Eisenhofer G, Goldstein DS, Kopin IJ, Crout JR. Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 2003;14:193-212.

  57. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. 
J Clin Endocrinol Metab 2003;88:2656-2666.

  58. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007;92:4069-4079.

  59. Pacak K, Linehan W, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315-329. 

  60. Plouin PF, Gimenez-Roqueplo AP. Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 2006;20:421-434.

  61. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005;90:2110-2116.

  62. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. 
Nat Clin Pract Endocrinol Metab 2007;3:92-102.

  63. Dluhy RG. Pheochromocytoma–death of an axiom. 
N Engl J Med 2002;346: 1486-1488.

  64. Barzon L, Sonino N, Fallo F, et al. Prevalence and natural history of adrenal incidentalomas. 
Eur J Endocrinol 2003;149:273-285.